In our opinion, the study of therapeutic efficiency of natural PPAR agonists (polyunsaturated fatty acids (PUFAs), eicosanoids, endocannabinoids, and endogenous specialized proresolving mediators (SPMs)) with a lower number of side effects than that of synthetic ones may be an incentive to develop a new combined therapy of asthma. This evidence concerns the gene PPARA and asthma.